CHEK1 and neoplasm: Chao et al. [169] found that the combination of a CHK1/2 inhibitor (AZD7762) with radiotherapy effectively initiated type I IFN signaling and T-cell response by accelerating immunogenic micronucleus formation and also increased the T-cell infiltration and transduction of immune-activating gene signals, thereby reducing tumor volume.